Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis.
- DOI
- 10.1007/s10549-009-0724-3
- Published
- 2010-01-08
- Container
- Breast Cancer Res Treat
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10549-009-0724-3,
title = {Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis.},
author = {van Herk-Sukel MP and van de Poll-Franse LV and Voogd AC and Nieuwenhuijzen GA and Coebergh JW and Herings RM.},
year = {2010},
journal = {Breast Cancer Res Treat},
doi = {10.1007/s10549-009-0724-3},
url = {https://doi.org/10.1007/s10549-009-0724-3}
}RIS
TY - JOUR TI - Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. AU - van Herk-Sukel MP AU - van de Poll-Franse LV AU - Voogd AC AU - Nieuwenhuijzen GA AU - Coebergh JW AU - Herings RM. PY - 2010 JO - Breast Cancer Res Treat DO - 10.1007/s10549-009-0724-3 UR - https://doi.org/10.1007/s10549-009-0724-3 ER -
APA
MP, V. H., LV, V. D. P., AC, V., GA, N., JW, C., & RM., H. (2010). Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis.. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-009-0724-3
Source records
- europe-pmc · retrieved 2026-09-25T06:40:55.790Z
- hal · retrieved 2026-09-25T06:40:55.880Z